Nurtec ODT vs Austedo
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Nurtec ODT | US Austedo | |
|---|---|---|
| Generic name | rimegepant | deutetrabenazine |
| Drug class | CGRP Receptor Antagonist | VMAT2 Inhibitor |
| Treats | Migraine (acute and preventive) | Tardive dyskinesia, Huntington's chorea |
| Category | Neurology | Neurology |
| Manufacturer | Pfizer | Teva |
| Year approved | 2020 | 2017 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $190M | $150M |
| Common side effects | Nausea, Stomach pain, Indigestion, Allergic reactions | Depression and suicidal thoughts (Huntington's), Drowsiness, Fatigue, Dry mouth |
Nurtec ODT
Frequently asked questions
Is Nurtec ODT or Austedo better?
Neither is universally "better." Nurtec ODT (rimegepant) and Austedo (deutetrabenazine) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Nurtec ODT and Austedo?
Nurtec ODT is a CGRP Receptor Antagonist made by Pfizer, while Austedo is a VMAT2 Inhibitor made by Teva. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Nurtec ODT has the larger estimated TV advertising budget of the two.